MCPP
1-(3-chlorophenyl)piperazine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
mCPP (meta-chlorophenylpiperazine) is a synthetic serotonergic compound of the piperazine class. It is the primary active metabolite of the antidepressant trazodone and a structural relative of TFMPP.[1] mCPP is a partial agonist at serotonin 5-HT₂C receptors, producing its effects by amplifying serotonergic tone while inducing serotonin release from nerve terminals.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1951 as a candidate antihistamine,[3] mCPP became the most extensively used probe of serotonin function in psychiatric research by the early 1990s.[4] It appeared on European recreational drug markets around 2004, frequently sold in tablets misrepresented as MDMA.[5] It remains unscheduled under international conventions, though several countries have imposed national controls.
Subjective effects include anxiety, dysphoria, depersonalization, stimulation, and appetite suppression. The experience is defined by its aversive character — a mounting tension and unease with minimal euphoria, distinguishing it sharply from the empathogenic warmth of MDMA despite superficial similarities in serotonergic mechanism.[5] Panic-like states, persistent agitation, and depersonalization are characteristic unsought effects.[6]
mCPP has low abuse liability and is classified as non-neurotoxic, though one fatality has been documented in a user with pre-existing asthma.[2][7] The primary risk is acute psychological distress compounded by extreme pharmacokinetic variability — identical doses produce up to 8-fold differences in blood levels between individuals due to genetic differences in drug metabolism.[8] Extensively characterized as a research probe but never subjected to controlled dose-escalation studies, mCPP's recreational pharmacology rests on community consensus rather than clinical data.
History[edit]
Discovery
mCPP was first synthesized in 1951 by Thomas H. Wicker Jr. during doctoral research at the University of Florida, as part of a series exploring potential antihistamine compounds.[3] The compound attracted little pharmacological attention for nearly three decades, until researchers in the late 1970s recognized its potential as a tool for probing serotonin function in the central nervous system.[1]
The serotonin probe era
By the mid-1980s, mCPP had become the dominant pharmacological challenge agent in psychiatric serotonin research. Administered to thousands of participants across studies of obsessive-compulsive disorder, depression, bulimia, panic disorder, and alcoholism, it produced measurable neuroendocrine responses — cortisol, prolactin, and hormone elevations — that served as biomarkers of central serotonergic sensitivity.[4][9] The landmark 1987 study by Zohar and Insel was among the first to deploy mCPP as a clinical probe, documenting acute exacerbation of OCD symptoms and providing early evidence for serotonergic mechanisms in the disorder.[10]
Recreational emergence and regulation
mCPP appeared on the European illicit drug market around 2004, initially in France, widely distributed in tablets sold as MDMA.[5][1] Its adoption was unusual in designer drug history: the compound offered few rewarding effects, and its anxiogenic profile made repeat use unappealing. Recreational uptake was driven by supply-side economics — ease of synthesis and uncontrolled legal status — rather than consumer demand.[5] New Zealand scheduled mCPP in 2008, Germany subsequently banned it, and the United Kingdom covered it under the Psychoactive Substances Act 2016.[3]
The name mCPP abbreviates meta-chlorophenylpiperazine, with meta denoting the chlorine atom's position on the phenyl ring. The compound carries no established street names — its recreational identity was defined by misrepresentation, typically sold under the MDMA brand in pressed pill form indistinguishable from ecstasy tablets.[11][12] Among forensic chemists, mCPP is notable for producing false-positive MDMA results on standard immunoassay drug screens, a property that complicates both criminal justice proceedings and clinical monitoring of patients receiving trazodone.[12][1]
Chemistry[edit]
Structural class
mCPP belongs to the phenylpiperazine family — compounds sharing a piperazine ring bonded directly to a phenyl group. The parent scaffold is 1-phenylpiperazine; mCPP is its meta-chloro substituted derivative. The position of the chlorine atom on the aromatic ring is pharmacologically critical: the meta substitution confers the high serotonin 5-HT₂C affinity that distinguishes mCPP from its ortho- and para-chloro analogs.[1]
The compound is also a metabolic product: CYP3A4 enzymes in the liver cleave trazodone, nefazodone, and etoperidone to generate mCPP as their primary active metabolite.[1]
Molecular properties
| Molecular formula | C₁₀H₁₃ClN₂ |
| Molecular weight | 196.67 g/mol |
The structure consists of a six-membered piperazine ring containing two nitrogen atoms, with a 3-chlorophenyl group bonded to one nitrogen.[13] mCPP contains no chirality centers and exists as a single achiral species — no stereoisomer considerations apply to its activity.
Structure-activity relationships
Within the phenylpiperazine series, the position and identity of the halogen substituent on the phenyl ring determines receptor selectivity. The meta-chloro placement is responsible for mCPP's preferential binding at 5-HT₂C over 5-HT₂A. The closely related compound TFMPP (1-(3-trifluoromethylphenyl)piperazine), which replaces the chlorine with a trifluoromethyl group at the same position, shares serotonergic activity but differs in receptor selectivity and recreational profile.[1]
Pharmacology[edit]
Mechanism of action
mCPP's primary pharmacological action is partial agonism at serotonin 5-HT₂C receptors.[4][14] This receptor mediates the majority of mCPP's behavioral, neuroendocrine, and anxiogenic effects in humans. Blocking studies using selective antagonists confirm the centrality of 5-HT₂C: SB-242084 blocks mCPP-induced behavioral changes in animal models,[14] ritanserin attenuates anxiety and prolactin release in humans,[15] and metergoline fully blocks both behavioral and hormonal responses in OCD patients.[16]
Beyond direct receptor activation, mCPP functions as a SERT substrate, triggering serotonin release from nerve terminals through transporter-mediated efflux — a mechanism shared with MDMA and fenfluramine.[1][17][2] This serotonin-releasing activity adds to the compound's overall serotonergic load but does not produce the long-term serotonin depletion seen with neurotoxic releasing agents.[2][18]
The interoceptive cue by which organisms recognize the mCPP drug state is specifically 5-HT₂C-mediated, as demonstrated in drug discrimination studies.[19] mCPP's discriminative stimulus is distinct from both anxiolytic and stimulant drug classes.
Pharmacokinetics
mCPP is eliminated with a half-life of approximately 2.5–7 hours. Oral bioavailability is highly variable, ranging from roughly 12% to over 80%, with peak blood levels differing up to 8-fold between individuals after the same oral dose.[8] This extreme variability is driven primarily by genetic differences in CYP2D6, the liver enzyme responsible for mCPP's primary metabolic pathway.
CYP2D6 converts mCPP to its principal breakdown product, para-hydroxy-mCPP.[20] Drugs that inhibit CYP2D6 — including cocaine, paroxetine, fluoxetine, and diltiazem — elevate mCPP blood levels, compounding both its intended and adverse effects.[20][21] When mCPP is generated as a metabolite of trazodone, the parent compound is converted by a different enzyme system (CYP3A4).[1]
The bioactivation of mCPP also produces a reactive intermediate that is normally neutralized by the body's defenses, raising theoretical concerns about liver stress during prolonged exposure.[22]
Neuroscience[edit]
Where it acts
mCPP's neural effects are mediated primarily through serotonergic circuits, with 5-HT₂C receptor activation as the dominant mechanism. Unlike classical stimulants, mCPP produces minimal activation of dopamine reward pathways, consistent with its lack of reinforcing properties and its failure as a recreational compound.[5] In cocaine-dependent patients, mCPP reveals serotonergic modulation of impulsivity and aggression through prefrontal circuits rather than direct dopaminergic mechanisms.[23]
Brain imaging studies show that mCPP reduces neural responses to food images in reward-associated regions, consistent with 5-HT₂C activation in circuits governing appetite and satiety.[24][25]
Why it matters
mCPP's anxiogenic effects represent one of the most reliably induced pharmacological anxiety states in human research, mediated by 5-HT₂C receptors in amygdala and prefrontal circuits.[4] Despite its serotonin-releasing activity, repeated administration does not cause long-term serotonin depletion — mCPP is non-neurotoxic, producing substantially lower transporter-level effects than compounds like MDMA.[2][18]
No evidence of mCPP-induced neuroplasticity has been published. 5-HT₂C agonism is not associated with the plasticity-promoting effects attributed to serotonin 2A receptor agonists such as classical psychedelics.
The specific neural circuit through which 5-HT₂C activation produces subjective anxiety has not been mapped by direct neuroimaging. The clinical significance of CYP2D6 poor metabolizer status for brain exposure and toxicity risk is unstudied.[8] Whether chronic low-level mCPP exposure from trazodone metabolism produces receptor adaptation — and whether this contributes to trazodone's therapeutic or adverse effects — remains an open question with direct clinical implications.[26] The neural basis of mCPP-induced depersonalization, documented across multiple psychiatric populations,[6] is also unknown.
Subjective Effects[edit]
The mCPP experience is predominantly aversive. Anxiety, dysphoria, and depersonalization define the core character at all documented dose levels, with minimal euphoria and no reinforcing hedonic quality. Intensity varies dramatically between individuals due to genetic differences in drug metabolism, making dose-response prediction unreliable. Set and setting modulate distress severity but do not alter the fundamentally anxiogenic nature of the experience.
mCPP bears superficial resemblance to MDMA through its serotonin-releasing mechanism and its frequent appearance in pressed pill form, but the subjective experience is qualitatively opposite: where MDMA produces warmth, empathy, and euphoria, mCPP produces tension, unease, and dysphoria. The comparison to low-dose amphetamine sometimes noted by users captures the stimulant component but misses the characteristic negative emotional tone that defines the mCPP experience.
Effect Grid
Pronounced anxiety and dysphoria become the dominant experience. Unlike typical stimulants, increased dose produces greater distress rather than greater euphoria. Depersonalization is possible. Headache is common. Cognitive effects include mild confusion and difficulty concentrating.
Appetite suppression is moderate and clearly noticeable. Temperature dysregulation may manifest as alternating warmth and chills. Mild tachycardia and blood pressure elevation. Stimulation is present but overshadowed by anxiogenic character.
Functional impairment from anxiety and dysphoria makes productive activity difficult. Duration of commitment is 4-8 hours including offset.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Nausea · Restlessness · Sexual arousal suppression · Increased urination · Vasoconstriction · Dizziness · Heart rate perception changes · Wakefulness · Muscle tension · Pupil dilation · Excessive sweating · Insomnia · Bodily heaviness · Dehydration sensation · Trembling · Bruxism
Increased urination · Dizziness · Heart rate perception changes · Wakefulness · Muscle tension · Pupil dilation · Excessive sweating · Insomnia · Bodily heaviness · Dehydration sensation · Trembling · Bruxism
Confusion
Emotional lability
Timeline
Initial awareness of mild stimulation and emerging restlessness. A subtle anxiogenic undercurrent begins without clear pharmacological signature. Highly variable onset timing due to CYP2D6 polymorphisms.
Anxiety intensifies and becomes clearly drug-induced. Sympathomimetic effects become apparent — heart rate elevation, possible temperature changes. Appetite suppression develops.
Maximum anxiety, dysphoria, and depersonalization. Neuroendocrine effects peak (cortisol, prolactin elevation). Temperature dysregulation most pronounced.
Gradual attenuation of anxiety and dysphoria. Residual fatigue, headache, and cognitive dulling persist. Appetite may begin returning.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- MDMA · other 5-HT2C agonists
Toxicity
Acute toxicity
No lethal dose has been established for mCPP in any species. The toxicity rating of "acute: moderate" is inferred from pharmacological class, not from empirical toxicity data.safety citation needed
One fatality is documented: a 20-year-old male with pre-existing allergic asthma who died of cardiorespiratory arrest after ingesting approximately 20 mg in a tablet sold as ecstasy.[7] The probable mechanism was serotonin-mediated airway constriction via 5-HT₂ receptors in lung tissue. Hair analysis confirmed first exposure. Asthma transforms mCPP from an unpleasant compound into a potentially lethal one.
One non-fatal overdose is documented: a female patient who ingested three tablets, reaching blood levels approximately 6 times the upper range seen during trazodone therapy.[27] Multiple other substances were present, including amphetamine and alcohol. Symptoms included anxiety, agitation, sedation, flushing, visual disturbances, and rapid heartbeat. She recovered with supportive care.
Neurotoxicity
mCPP is non-neurotoxic. Despite causing large acute serotonin elevations, repeated administration does not produce long-term serotonin depletion — in direct contrast to fenfluramine and MDMA.[2][18]
Serotonin syndrome
mCPP's combined receptor activation and serotonin-releasing activity create significant potential for serotonin syndrome when combined with other serotonergic agents.[5] No published case of serotonin syndrome from mCPP alone has been identified, but the pharmacological basis is well established. Chronic mCPP generation from trazodone metabolism poses ongoing serotonergic risk that may be clinically underappreciated.[26]
Liver concerns
Metabolism of mCPP produces a reactive intermediate that the body normally neutralizes.[22] No clinical liver damage has been linked to mCPP, but this pathway raises theoretical concerns during chronic exposure — particularly relevant for patients receiving trazodone, who generate mCPP continuously.
Trazodone-generated exposure
Patients receiving trazodone, nefazodone, or etoperidone are continuously exposed to mCPP as an active metabolite.[1] Clinically significant mCPP levels may persist around the clock in treated patients.[26] False-positive urine MDMA testing in trazodone patients is a documented forensic complication.[12]
Psychological risks
Anxiety is the most consistently documented effect of mCPP and represents a genuine clinical risk.[4] At clinical challenge doses, mCPP reliably induces panic-like states, acute dysphoria, and depersonalization in both healthy volunteers and psychiatric patients.[6] OCD patients experience acute symptom worsening.[10]
Individuals with pre-existing anxiety disorders, OCD, borderline personality disorder, or psychotic spectrum conditions face heightened risk of severe psychological distress.[5] Depersonalization occurs significantly more often than with placebo, correlating with panic induction but dissociable from baseline anxiety or depression.[6]
The psychological risk profile is atypical for a recreationally available compound: the primary effects are aversive, and the risk of acute distress is not balanced by hedonic benefit.
Tolerance and dependence
mCPP has low abuse and dependence potential. The compound does not exhibit reinforcing properties in standard animal or human paradigms.[5] Recreational users report few positive subjective effects. Drug discrimination studies confirm that mCPP's internal cue is distinct from both anxiolytic and stimulant drug classes.[19]
No controlled human study on tolerance development has been published. Indirect evidence suggests that 5-HT₂C receptors may desensitize with repeated agonist exposure.citation needed No withdrawal has been documented.
Drug interactions
Serotonergic combinations
Any compound that increases serotonergic transmission compounds the serotonin syndrome risk. This includes SSRIs, SNRIs, MAOIs, triptans, and tramadol.[5] Prior MDMA use alters mCPP neuroendocrine responses, initially blunting and later enhancing them, consistent with MDMA-induced serotonergic changes.[28][29] Acute co-administration poses additive serotonergic risk.
CYP2D6 inhibitors
Cocaine inhibits CYP2D6, reducing mCPP breakdown and raising blood levels.[20] Forensic evidence documents mCPP as an adulterant of cocaine, creating real-world scenarios where both compounds are present simultaneously.[20] Other CYP2D6 inhibitors — including paroxetine, fluoxetine, and diltiazem — produce equivalent elevations.[21]
Trazodone and related antidepressants
Patients receiving trazodone, nefazodone, or etoperidone are already generating mCPP through normal metabolism.[1] Additional mCPP exposure would produce additive effects. Trazodone-treated patients maintain clinically significant mCPP levels continuously.[26]
Alcohol
Alcohol was present in the only documented non-fatal mCPP overdose.[27] No controlled study of the mCPP–alcohol interaction has been published. Additive depressant effects are pharmacologically plausible but uncharacterized.
Interaction severity notes
Tramadol and cocaine interactions are listed as potentially lethal. No published case reports of fatal outcomes from these specific combinations have been identified. The serotonin syndrome mechanism for tramadol and the CYP2D6 inhibition mechanism for cocaine are pharmacologically well-supported, but the lethal severity classification for both lacks direct case documentation.safety citation needed
Contraindications
Asthma and reactive airways disease
The single documented mCPP fatality occurred in a patient with pre-existing allergic asthma.[7] Asthma and reactive airways disease constitute an absolute contraindication for intentional mCPP exposure. Patients with asthma receiving trazodone may also warrant clinical monitoring.
Psychiatric conditions
Pre-existing anxiety disorders, OCD, borderline personality disorder, and psychotic spectrum conditions increase the risk of severe psychological distress.[5] mCPP reliably worsens OCD symptoms[10] and induces depersonalization in vulnerable populations.[6]
Concurrent serotonergic medication
SSRIs, SNRIs, MAOIs, triptans, or tramadol constitute a relative-to-absolute contraindication depending on the agent and dose, due to serotonin syndrome risk.[5] MAOI co-administration carries the highest risk.
CYP2D6 poor metabolizer status
Individuals with CYP2D6 poor metabolizer genotype or those taking CYP2D6 inhibitors will achieve substantially higher mCPP blood levels from the same dose, increasing all dose-dependent risks.[20][21]
Cardiovascular conditions
mCPP produces mild elevations in blood pressure and heart rate.[9][15] Pre-existing heart conditions represent a relative contraindication.
Harm Reduction[edit]
Forms & Identification
mCPP is most commonly encountered in pressed tablet form, often stamped with logos identical to those used on MDMA tablets.[11][12] Visual inspection cannot distinguish mCPP from MDMA. Reagent testing is essential, as mCPP and MDMA produce distinct color reactions with standard reagent kits.
mCPP cross-reacts with Ecstasy immunoassay urine tests, producing false-positive MDMA results.[12] This affects both recreational users and patients taking trazodone. Only confirmatory laboratory testing (GC-MS or LC-MS) can reliably distinguish mCPP from MDMA in biological samples.
Guidelines
- Test all tablets with reagent kits before ingestion — mCPP pressed as ecstasy is common
- Start with the lowest available amount and wait at least 2 hours before considering re-dosing, given the extreme pharmacokinetic variability between individuals[8]
- Have a sober, trusted companion present
- Ensure a calm, familiar environment with easy access to quiet space
- Stay hydrated but avoid excessive water intake
- If effects are primarily anxious and dysphoric rather than empathogenic, consider that the substance may not be what was expected
Set & Setting
Given mCPP's fundamentally anxiogenic character, set and setting take on particular importance. Environments that are unfamiliar, crowded, or high-stimulation amplify the anxiety and dysphoria that define the experience. Individuals who unknowingly consume mCPP believing it to be MDMA face compounded distress from both the aversive pharmacological effects and the realization that the expected experience will not arrive.
Aftercare & integration. The mCPP experience is predominantly negative, and aftercare focuses on recovery from acute psychological distress rather than integration of meaningful content. Anxiety and dysphoria typically resolve within hours of the drug's elimination, but residual tension, low mood, and fatigue may persist for a day.
Rest and adequate sleep are the primary recovery tools. Familiar environments, trusted company, and light nutrition support the return to baseline. If depersonalization symptoms persist beyond 24 hours, consider consulting a healthcare provider.
Recovery & Support
mCPP has low dependence potential, and compulsive use patterns are rare given the compound's aversive effect profile. Most exposure is inadvertent — from tablets sold as MDMA — rather than sought. For individuals experiencing repeated involuntary exposure through adulterated drug supply, harm reduction services and drug checking programs offer the most effective pathway to avoiding future mCPP encounters.
Patients receiving trazodone who experience adverse effects attributable to mCPP metabolite accumulation should discuss alternatives with their prescribing physician.[26] Support resources for substance-related concerns include SAMHSA's National Helpline (1-800-662-4357) and equivalent services in other jurisdictions.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Difficulty breathing or wheezing (especially in people with asthma), chest pain, severe uncontrollable panic, loss of consciousness, high body temperature, rigid muscles, or rapid involuntary eye movements. The critical distinction between uncomfortable and dangerous centers on breathing difficulty, chest symptoms, or complete loss of contact with reality.
Immediate steps:
- 1. Call emergency services if breathing difficulty, chest pain, seizure, or loss of consciousness occurs
- 2. Keep the person in a quiet, calm environment
- 3. If unconscious but breathing, place in the recovery position
- 4. Monitor breathing continuously — the documented fatality involved progressive respiratory failure
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (mCPP or piperazine), estimated amount taken, time of ingestion, and current symptoms. Note any pre-existing conditions, especially asthma. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Legal Status[edit]
mCPP remains unscheduled under international drug control conventions. No listing under the 1961, 1971, or 1988 UN Conventions has been identified.[5] National responses have been fragmented, with some jurisdictions imposing specific controls and others relying on blanket psychoactive substance legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not controlled under the Controlled Substances Act. The Federal Analogue Act may apply if sold for human consumption.citation needed |
| New Zealand | Class C (Misuse of Drugs Act 1975) | Scheduled effective April 2008; possession illegal from October 2008.[3] |
| Germany | Controlled substance | Banned; specific scheduling date not confirmed in primary sources.[3] |
| United Kingdom | Prohibited | Covered under the Psychoactive Substances Act 2016 blanket prohibition.[3] |
| Australia | Not confirmed | No primary source identified; verification via TGA/Poisons Standard recommended.citation needed |
| Canada | Not confirmed | No primary source identified.citation needed |
| European Union | Variable by member state | No EU-wide scheduling; some member states have national controls.[5] |
Forensic considerations
mCPP cross-reacts with the Ecstasy EMIT II immunoassay, producing false-positive MDMA results in standard urine drug testing.[12] This affects both recreational mCPP users and patients receiving therapeutic trazodone.[1] The implications extend to workplace drug testing, criminal justice proceedings, and clinical monitoring programs where a positive MDMA screen may trigger consequences based on a misidentified substance.
references
- [1]
- [2] ^abcdefBaumann MH, Bulling S, Benaderet TS, Saha K, Ayestas MA, Partilla JS, Ali SF, Stockner T, Rothman RB, Sandtner W, Sitte HH (2014) Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates — Neuropsychopharmacology doi:10.1038/npp.2013.331
- [3]
- [4]
- [5]
- [6]